Initial in vivo studies examining the effect of adiponectin on atherosclerosis demonstrated that adenovirus-mediated overexpression of adiponectin (33) and gAd treatment (23) in apolipoprotein (apo) E-deficient mice resulted in reduced atherosclerosis. Here, ADIPOQ is linked to atherosclerosis.